Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy
ConditionPregnancy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-35
SponsorETH Zurich
This study evaluates iron absorption from three antenatal supplements, 30 mg MMS, 60 mg MMS, and 60 mg IFA, in 50 pregnant Kenyan women in their second trimester. Using a randomized crossover design and stable iron isotopes, we will compare bioavailability in both fasted and fed states. Additionally, the trial will investigate if daily dosing triggers a hepcidin response that inhibits subsequent absorption, testing whether alternate-day dosing is a more effective strategy for treating iron deficiency.
female
pregnant at gestational age 12 (±1) weeks (dated by ultrasound)
age 18 to 35 y
Hb concentration ≥80 g/L
severe anemia (defined as Hb <80 g/L)
malaria
sickle cell disease (SS and SC)
hemoglobin C disease (CC).